Abbildung 12: Telmisartan - LVH
Telmisartan reduced LVH compared with carvedilol despite similar reductions in blood pressure.1 The 84 patients in this study had hypertension and LVH, and received telmisartan 80 mg or carvedilol 25 mg for 44 weeks. LVM was measured by MRI (results shown in this slide) and three-dimensional echocardiography. Both treatments reduced 24-h mean SBP/DBP by similar amounts (telmisartan by 31/19 mmHg, carvedilol by 29/17 mmHg, P=ns). However, telmisartan reduced LVM significantly more than did carvedilol. Similar effects were seen using echocardiography. Galzerano D, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared to carvedilol on left ventricular mass: a multicenter randomized study. 53rd Annual Scientific Session of the American College of Cardiology, 2004, New Orleans, USA. 2004.